Clinical trial · Observational
Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer
The Clinical Outcome of Adjuvant Chemotherapy in Conjunction With Traditional Chinese Medicine in Breast Cancer Patients -a Observational Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This 2-year trial is intended to be used to study breast cancer patients through forward-looking generation design through collaboration between Chinese and Western medical teams. The whole study consists of 2 stages, stage I comprises a cross-sectional study-baseline and stage II is a cohort for outcome evaluation and follow-up study across a 3-year period. To provide an empirical basis for combined TCM treatment in the Breast Cancer Research Team and to publish that as a reference for future TCM and Western medicine in integrative cancer treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early-stage Breast Cancer | Early Stage Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chinese herbal medicine | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- adjuvant chemotherapy combined with Chinese herbal medicine
- interventionNames
- Combination Product: Chinese herbal medicine
- label
- Cohort 2
- description
- adjuvant chemotherapy only
- interventionNames
- Combination Product: Chinese herbal medicine
Primary outcomes (1)
- measure
- disease-free survival
- timeFrame
- 3 years
- description
- 3-year disease-free survival
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Aged \> 20 years old female patients; * Patients with histologically proven stage 1-3 breast cancer after surgery; * The duration from the end of radical surgery to the beginning of the trail is less than 1 month; * ECOG score is 0-2 points; * Agreed to participate in this study and signed informed consent. Exclusion Criteria: * Combined with inadequate heart, liver, kidney and hematopoietic function and other serious diseases; * Pregnant and lactating women; * Patients with a history of mental illness; * Patients with distant metastasis and/or expected lifetime less than 3 months; * Patients undergoing other medicinal herbs outside our hospital.
References
Publications (2)
- DERIVEDChin CY, Wu SC, Wang HY, Liu CT, Huang YC, Tsai MY. Efficacy of Chinese Herbal Medicine in Managing Hot Flushes in Breast Cancer Patients on Adjuvant Chemotherapy: A Clinical Investigation. Integr Cancer Ther. 2025 Jan-Dec;24:15347354251398843. doi: 10.1177/15347354251398843. Epub 2025 Nov 29. PMID 41317109
- DERIVEDLiu CT, Chen YH, Huang YC, Chen SY, Tsai MY. Chemotherapy in conjunction with traditional Chinese medicine for survival of patients with early female breast cancer: protocol for a non-randomized, single center prospective cohort study. Trials. 2019 Dec 17;20(1):741. doi: 10.1186/s13063-019-3848-8. PMID 31847861